Cited by 6,097Breast Cancer Treatment StudiesCancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Open access

METABRIC Group, Curtis, Christina, Shah, Sohrab P., Chin, Suet-Feung, Turashvili, Gulisa, Rueda, Oscar M., Dunning, Mark J., Speed, Doug, Lynch, Andy G., Samarajiwa, Shamith, Yuan, Yinyin, Gräf, Stefan, Ha, Gavin, Haffari, Gholamreza, Bashashati, Ali, Russell, Roslin, McKinney, Steven, Langerød, Anita, Green, Andrew, Provenzano, Elena, Wishart, Gordon, Pinder, Sarah, Watson, Peter, Markowetz, Florian, Murphy, Leigh, Ellis, Ian, Purushotham, Arnie, Børresen-Dale, Anne-Lise, Brenton, James D., Tavaré, Simon, Caldas, Carlos, Aparicio, Samuel·2012·Nature

DOI 10.1038/nature10983PMC PMC3440846

Open this paper in CoChat — free account

Abstract

The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of the genome and transcriptome from representative numbers of patients. We present an integrated analysis of copy number and gene expression in a discovery and validation set of 997 and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants (copy number variants and single nucleotide polymorphisms) and acquired somatic copy number aberrations (CNAs) were associated with expression in ~40% of genes, with the landscape dominated by cis- and trans-acting CNAs. By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and MAP2K4. Unsupervised analysis of paired DNA–RNA profiles revealed novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort. These include a high-risk, oestrogen-receptor-positive 11q13/14 cis-acting subgroup and a favourable prognosis subgroup devoid of CNAs. Trans-acting aberration hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the ‘CNA-devoid’ subgroup and a basal-specific chromosome 5 deletion-associated mitotic network. Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature10983

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Self-citation
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Self-citation
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R. J., Hastie, T. J., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,931
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,411
Self-citation
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,309
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T., Shih, I., Mao, T., Nakayama, K., Roden, R. B. S., Glas, R., Slamon, D. J., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,218

Flagged first, then by citations

Show all 32 references

Sorted by citations

Items 301–400 of 1,028

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Mérino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 195
Modeling Breast Cancer Using CRISPR-Cas9–Mediated Engineering of Human Breast Organoids
Dekkers, J. F., Whittle, J. R., Vaillant, F., Chen, H., Dawson, C. A., Liu, K., Geurts, M. H., Herold, M. J., Clevers, H. C., Lindeman, G. J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz196 · Cited by 194
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
Hubert, P., Roncarati, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001966 · Cited by 191
Functionalized liposomes for targeted breast cancer drug delivery
Nel, J., Elkhoury, K., Velot, É., Bianchi, A., Acherar, S., Francius, G., Tamayol, A., Grandemange, S., & Arab‐Tehrany, E. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.027 · Cited by 193
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins
Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2763 · Cited by 184
In vivomodels in breast cancer research: progress, challenges and future directions
Holen, I., Speirs, V., Morrissey, B., & Blyth, K. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028274 · Cited by 183
Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer
Blasco-Benito, S., Seijo-Vila, M., Caro-Villalobos, M., Tundidor, I., Andradas, C., García-Taboada, E., Wade, J., Smith, S., Guzmán, M., Pérez-Gómez, E., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.06.025 · Cited by 183
FOXM1 (Forkhead box M1) in Tumorigenesis
Wierstra, I. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 190
Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
Paquet, É. R., & Hallett, M. T. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju357 · Cited by 186
Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
Győrffy, B., Bottai, G., Fleischer, T., Munkácsy, G., Budczies, J., Paladini, L., Børresen‐Dale, A., Kristensen, V. N., & Santarpia, L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29684 · Cited by 182
Self-citation
Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis
Verma, N., Vinik, Y., Saroha, A., Nair, N. U., Ruppin, E., Mills, G. B., Karn, T., Dubey, V., Khera, L., Raj, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba8968 · Cited by 184
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response
Nagarajan, S., Rao, S. V., Sutton, J., Cheeseman, D., Dunn, S., Papachristou, E. K., Prada, J.-E. G., Couturier, D., Kumar, S. S., Kishore, K., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0541-5 · Cited by 183
Self-citation
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Siegel, M. B., He, X., Hoadley, K. A., Hoyle, A. P., Pearce, J. B., Garrett, A., Kumar, S., Moylan, V. J., Brady, C., Swearingen, A. E. D. V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96153 · Cited by 186
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Aftimos, P. G., Oliveira, M., Irrthum, A., Fumagalli, D., Sotiriou, C. P., Gal‐Yam, E. N., Robson, M. E., Ndozeng, J., Leo, A. D., Ciruelos, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1647 · Cited by 180
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
Morel, A., Ginestier, C., Pommier, R. M., Cabaud, O., Ruiz, E. M., Wicinski, J., Devouassoux‐Shisheboran, M., Combaret, V., Finetti, P., Chassot, C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4323 · Cited by 189
The Spectrum of Triple-Negative Breast Disease
Geyer, F. C., Pareja, F. G., Weigelt, B., Rakha, E. A., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.03.016 · Cited by 189
Self-citation
Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix
Kay, E. J., Paterson, K., Riera‐Domingo, C., Sumpton, D. P., Däbritz, J. H. M., Tardito, S., Boldrini, C., Hernandez-Fernaud, J. R., Athineos, D., Dhayade, S., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00582-0 · Cited by 197
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Engebraaten, O., Vollan, H. K. M., & Børresen‐Dale, A. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.033 · Cited by 178
Self-citation
NRF2 Induction Supporting Breast Cancer Cell Survival Is Enabled by Oxidative Stress–Induced DPP3–KEAP1 Interaction
Lu, K., Alcivar, A. L., Ma, J., Foo, T. K., Zywea, S., Mahdi, A., Huo, Y., Kensler, T. W., Gatza, M. L., & Xia, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2204 · Cited by 181
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers
Elion, D. L., Jacobson, M. E., Hicks, D. J., Rahman, B., Sanchez, V. M., Ericsson, P. I. G., Fedorova, O., Pyle, A. M., Wilson, J. T., & Cook, R. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0730 · Cited by 178
A novel approach for data integration and disease subtypingPreprint
Nguyen, T., Tagett, R., Diaz, D., & Drăghici, S. (2017) · Genome Research · doi:10.1101/gr.215129.116 · Cited by 183
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy
Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e31 · Cited by 181
Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis
Tan, V. Y., Lewis, S. J., Adams, J. C., & Martin, R. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-52 · Cited by 179
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development
Costa, R. L. B., Shah, A. N., Santa-Maria, C. A., Cruz, M. R. D. S., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.010 · Cited by 177
Circulating tumour cells and cell-free DNA as tools for managing breast cancer
Mattos‐Arruda, L. D., Cortés, J., Santarpia, L., Vivancos, A. P., Tabernero, J. M., Reis-Filho, J. S., & Seoane, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.80 · Cited by 176
Re-definition of claudin-low as a breast cancer phenotype
Fougner, C., Bergholtz, H., Norum, J. H., & Sørlie, T. (2020) · Nature Communications · doi:10.1038/s41467-020-15574-5 · Cited by 175
Inferring biological tasks using Pareto analysis of high-dimensional data
Hart, Y., Sheftel, H., Hausser, J., Székely, P., Moshe, N. B. B., Kohanim, Y. K., Tendler, A., Mayo, A., & Alon, U. S. (2015) · Nature Methods · doi:10.1038/nmeth.3254 · Cited by 174
Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities
Dieci, M. V., Orvieto, E., Dominici, M., Conte, P., & Guarneri, V. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0108 · Cited by 174
ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer
Kumar, S., Wilkes, D. W., Samuel, N., Blanco, M. A., Nayak, A., Alicea-Torres, K. M., Gluck, C. B., Sinha, S., Gabrilovich, D. I., & Chakrabarti, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99673 · Cited by 174
A Critical Review on the Synthesis of Natural Sodium Alginate Based Composite Materials: An Innovative Biological Polymer for Biomedical Delivery Applications
Ahmad, A., Mubarak, N. M., Jannat, F. T., Ashfaq, T., Santulli, C., Rizwan, M., Najda, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., Hussain, S., et al. (2021) · Processes · doi:10.3390/pr9010137 · Cited by 175
Tackling the Diversity of Triple-Negative Breast Cancer
Turner, N. C., & Reis-Filho, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0915 · Cited by 175
Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging
Rios, A. C., Capaldo, B. D., Vaillant, F., Pal, B., van Ineveld, R. L., Dawson, C. A., Chen, Y., Nolan, E., Fu, N. Y., Jackling, F. C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.010 · Cited by 175
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
Michaut, M., Chin, S., Majewski, I. J., Severson, T., Bismeijer, T., de Koning, L., Peeters, J. K., Schouten, P. C., Rueda, O. M., Bosma, A. J., et al. (2016) · Scientific Reports · doi:10.1038/srep18517 · Cited by 174
Self-citation
Deep Survival Machines : Fully Parametric Survival Regression and Representation Learning for Censored Data With Competing Risks
Nagpal, C., Li, X., & Dubrawski, A. W. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3052441 · Cited by 190
miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer
Li, H., Liang, J.-L., Kuo, Y., Lee, H.-H., Calkins, M. J., Chang, H.-T., Lin, F., Chen, Y., Hsu, T., Hsiao, M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0918-2 · Cited by 169
RNA sequencing of cancer reveals novel splicing alterations
Eswaran, J., Horvath, A., Godbole, S., Reddy, S. D. N., Mudvari, P., Ohshiro, K., Cyanam, D., Nair, S. S., Fuqua, S. A. W., Polyák, K., et al. (2013) · Scientific Reports · doi:10.1038/srep01689 · Cited by 176
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Collaborators, G. S., Fachal, L., Collaborators, E., KConFab Investigators, HEBON Investigators, ABCTB Investigators, Aschard, H., Beesley, J., Barnes, D. R., Allen, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0537-1 · Cited by 168
Genomics to select treatment for patients with metastatic breast cancer
André, F., Filleron, T., Kamal, M. T., Mosele, F., Arnedos, M., Dalenc, F., Sablin, M., Campone, M., Bonnefoi, H. R., Lefeuvre‐Plesse, C., et al. (2022) · Nature · doi:10.1038/s41586-022-05068-3 · Cited by 167
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer
Wu, T.-C., Xu, K., Martínek, J., Young, R. R., Banchereau, R., George, J., Turner, J., Kim, K. I., Zurawski, S., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0413 · Cited by 168
Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
Jenkins, E. O., Deal, A. M., Anders, C. K., Prat, A., Perou, C. M., Carey, L. A., & Muss, H. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0184 · Cited by 165
Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma
Zhu, Y., Li, H., Guo, W., Drukker, K., Lan, L., Giger, M. L., & Ji, Y. (2015) · Scientific Reports · doi:10.1038/srep17787 · Cited by 165
Mutant p53 Reprograms TNF Signaling in Cancer Cells through Interaction with the Tumor Suppressor DAB2IP
Minin, G. D., Bellazzo, A., Ferro, M. D., Chiaruttini, G., Nuzzo, S., Bicciato, S., Piazza, S., Rami, D., Bulla, R., Sommaggio, R., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.10.013 · Cited by 165
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
Petrocca, F., Altschuler, G. M., Tan, S. M., Mendillo, M. L., Yan, H., Jerry, D. J., Kung, A. L., Hide, W. A., Ince, T. A., & Lieberman, J. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.008 · Cited by 165
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo‐Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 169
Self-citation
Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting
Liu, W., Xie, L., He, Y.-H., Wu, Z.-Y., Liu, L.-X., Bai, X., Deng, D.-X., Xu, X., Liao, L.-D., Lin, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25202-5 · Cited by 178
Matrix metalloproteinases as drivers and therapeutic targets in breast cancer
Radisky, E. S. (2015) · Frontiers in bioscience · doi:10.2741/4364 · Cited by 168
FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3
Jozwik, K. M., Chernukhin, I. V., Sérandour, A. A., Nagarajan, S., & Carroll, J. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.028 · Cited by 173
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Chae, Y. K., Hong, F., Vaklavas, C., Cheng, H. H., Hammerman, P. S., Mitchell, E. P., Zwiebel, J. A., Ivy, S. P., Gray, R. J., Li, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02630 · Cited by 164
Combined Single‐Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination
Liu, Y., Ge, J., Chen, Y., Liu, T., Chen, L., Liu, C., Ma, D., Chen, Y., Cai, Y., Xu, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202205395 · Cited by 167
Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer
Jadaliha, M., Zong, X., Malakar, P., Ray, T., Singh, D. K., Freier, S. M., Jensen, T., Prasanth, S. G., Karni, R., Ray, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9622 · Cited by 163
CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer
Craven, K. E., Gökmen‐Polar, Y., & Badve, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83913-7 · Cited by 163
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
Mérino, D., Lok, S. W., Visvader, J. E., & Lindeman, G. J. (2015) · Oncogene · doi:10.1038/onc.2015.287 · Cited by 164
p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling
Memmi, E. M., Sanarico, A. G., Giacobbe, A., Peschiaroli, A., Frezza, V., Cicalese, A., Pisati, F., Tosoni, D., Zhou, H., Tonon, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500762112 · Cited by 162
Changes of N6-methyladenosine modulators promote breast cancer progression
Wu, L., Wu, D., Ning, J., Liu, W., & Zhang, D. (2019) · BMC Cancer · doi:10.1186/s12885-019-5538-z · Cited by 162
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3521 · Cited by 161
Self-citation
The complex genetic landscape of familial breast cancer
Melchor, L., & Benitez, J. J. (2013) · Human Genetics · doi:10.1007/s00439-013-1299-y · Cited by 174
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 163
Detecting repeated cancer evolution from multi-region tumor sequencing data
Caravagna, G., Giarratano, Y., Ramazzotti, D., Tomlinson, I. P. M., Graham, T. A., Sanguinetti, G., & Sottoriva, A. (2018) · Nature Methods · doi:10.1038/s41592-018-0108-x · Cited by 162
Heterogeneity within molecular subtypes of breast cancer
Turner, K. M., Yeo, S. K., Holm, T. M., Shaughnessy, E., & Guan, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00109.2021 · Cited by 171
Spatially Resolved Metabolic Phenotyping of Breast Cancer by Desorption Electrospray Ionization Mass Spectrometry
Guenther, S., Muirhead, L. J., Speller, A. V. M., Golf, O., Strittmatter, N., Ramakrishnan, R., Goldin, R. D., Jones, E. A., Veselkov, K., Nicholson, J. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2258 · Cited by 159
The mutational landscape of phosphorylation signaling in cancer
Reimand, J., Wagih, O., & Bader, G. D. (2013) · Scientific Reports · doi:10.1038/srep02651 · Cited by 163
The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells
Menéndez, J. A., Joven, J., Cufí, S., Corominas-Faja, B., Oliveras‐Ferraros, C., Cuyàs, E., Martı́n-Castillo, B., López‐Bonet, E., Alarcón, T., & Vázquez‐Martín, A. (2013) · Cell Cycle · doi:10.4161/cc.24479 · Cited by 165
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence
Goh, J. Y., Feng, M., Wang, W., Oguz, G., Yatim, S. M. J. M., Lee, P. L., Bao, Y., Lim, T. H., Wang, P., Tam, W. L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4405 · Cited by 158
Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer
Sun, J., Huang, J., Lan, J., Zhou, K., Gao, Y., Song, Z., Deng, Y., Liu, L., Dong, Y., & Liu, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0986-8 · Cited by 158
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics
Hoang, D.-T., Dinstag, G., Shulman, E. D., Hermida, L. C., Ben-Zvi, D. S., Elis, E., Caley, K., Sammut, S.-J., Sinha, S., Sinha, N., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00793-2 · Cited by 157
Self-citation
Intratumor Heterogeneity in Breast Cancer
de Beça, F. F., & Polyák, K. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_7 · Cited by 160
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
Kirilovsky, A., Marliot, F., Sissy, C. E., Haicheur, N., Galon, J., & Pagès, F. (2016) · International Immunology · doi:10.1093/intimm/dxw021 · Cited by 159
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer
Heindl, A., Šestak, I., Naidoo, K., Cuzick, J. M., Dowsett, M., & Yuan, Y. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx137 · Cited by 162
Self-citation
TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer
Good, C. R., Panjarian, S. B., Kelly, A. D., Madžo, J., Patel, B. G., Jelı́nek, J., & Issa, J. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2082 · Cited by 157
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Prat, A., Guarneri, V., Pascual, T., Brasó‐Maristany, F., Sanfeliu, E., Paré, L., Schettini, F., Martínez, D., Jares, P., Griguolo, G., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103801 · Cited by 157
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Mazzu, Y. Z., Armenia, J., Chakraborty, G., Yoshikawa, Y., Coggins, S. A., Nandakumar, S., Gerke, T. A., Pomerantz, M. M., Qiu, X., Zhao, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4046 · Cited by 156
Thrombospondin-4 mediates TGF-β-induced angiogenesis
Muppala, S., Xiao, R., Krukovets, I., Verbovetskiy, D., Yendamuri, R. S., Habib, N. A., Raman, P., Plow, E. F., & Stenina‐Adognravi, O. (2017) · Oncogene · doi:10.1038/onc.2017.140 · Cited by 155
Etiologic, Phenomenologic, and Endophenotypic Overlap of Schizophrenia and Bipolar Disorder
Pearlson, G. D. (2015) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032814-112915 · Cited by 154
Lipid phosphate phosphatases and their roles in mammalian physiology and pathology
Tang, X., Benesch, M. G. K., & Brindley, D. N. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r058362 · Cited by 154
BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
Khaled, W. T., Lee, S. C., Stingl, J., Chen, X., Ali, H. R., Rueda, O. M., Hadi, F., Wang, J., Yu, Y., Chin, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6987 · Cited by 158
Self-citation
Targeting Akt3 Signaling in Triple-Negative Breast Cancer
Chin, Y. R., Yoshida, T., Marusyk, A., Beck, A. H., Polyák, K., & Toker, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2175 · Cited by 157
Decision support systems for personalized and participative radiation oncology
Lambin, P., Zindler, J. D., Vanneste, B. G. L., Voorde, L. V. D., Eekers, D. B. P., Compter, I., Panth, K. M., Peerlings, J., Larue, R. T. H. M., Deist, T. M., et al. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.006 · Cited by 162
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling
Altea‐Manzano, P., Doglioni, G., Liu, Y., Cuadros, A. M., Nolan, E., Fernández-García, J., Wu, Q., Planque, M., Laue, K., Cidre‐Aranaz, F., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00513-2 · Cited by 158
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
Wein, L., & Loi, S. (2017) · The Breast · doi:10.1016/j.breast.2017.06.023 · Cited by 153
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
Karn, T., Jiang, T., Hatzis, C., Sänger, N., El‐Balat, A., Rody, A., Holtrich, U., Becker, S., Bianchini, G., & Pusztai, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2140 · Cited by 156
A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases
Oliveri, S., Ferrari, F., Manfrinati, A., & Pravettoni, G. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00624 · Cited by 153
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
Bedognetti, D., Spivey, T., Zhao, Y., Uccellini, L., Tomei, S., Dudley, M. E., Ascierto, M. L., Giorgi, V. D., Liu, Q., Delogu, L. G., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.557 · Cited by 153
UNSUPERVISED FEATURE CONSTRUCTION AND KNOWLEDGE EXTRACTION FROM GENOME-WIDE ASSAYS OF BREAST CANCER WITH DENOISING AUTOENCODERS
Tan, J., Ung, M. H., Cheng, C., & Greene, C. S. (2014) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814644730_0014 · Cited by 152
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients
Fey, D., Halász, M., Dreidax, D., Kennedy, S. P., Hastings, J. F., Rauch, N., Muñoz, A. G., Pilkington, R., Fischer, M., Westermann, F., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab0990 · Cited by 152
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
The molecular diversity of Luminal A breast tumors
Ciriello, G., Sinha, R., Hoadley, K. A., Skanderup, A. J., Reva, B. A., Perou, C. M., Sander, C., & Schultz, N. D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2699-3 · Cited by 151
Distinct Copy Number, Coding Sequence, and Locus Methylation Patterns UnderlieRhg1-Mediated Soybean Resistance to Soybean Cyst Nematode
Cook, D. E., Bayless, A. M., Wang, K., Guo, X., Song, Q., Jiang, J., & Bent, A. F. (2014) · PLANT PHYSIOLOGY · doi:10.1104/pp.114.235952 · Cited by 155
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer
Radisky, E. S., Raeeszadeh‐Sarmazdeh, M., & Radisky, D. C. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26185 · Cited by 152
ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation
Monypenny, J., Milewicz, H., Flores‐Borja, F., Weitsman, G. E., Cheung, A., Chowdhury, R., Burgoyne, T., Arulappu, A., Lawler, K., Barber, P. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.066 · Cited by 151
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
Xu, J., Liu, Y., Li, Y., Wang, H., Stewart, S., der Jeught, K. V., Agarwal, P., Zhang, Y., Liu, S., Zhao, G., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0381-6 · Cited by 153
Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights
Anestis, A., Zoi, I., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · Molecules · doi:10.3390/molecules25020358 · Cited by 157
A human breast atlas integrating single-cell proteomics and transcriptomics
Gray, G. K., Li, C. M.-C., Rosenbluth, J. M., Selfors, L. M., Girnius, N., Lin, J., Schackmann, R. C. J., Goh, W. L., Moore, K., Shapiro, H., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.05.003 · Cited by 156
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Ferrari, A., Vincent-Salomon, A., Pivot, X., Sertier, A.-S., Thomas, E., Tonon, L., Boyault, S., Mulugeta, E., Treilleux, I., MacGrogan, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms12222 · Cited by 150
FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer
Han, B., Qu, Y., Jin, Y., Yu, Y., Deng, N., Wawrowsky, K., Zhang, X., Li, N., Bose, S., Wang, Q., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.063 · Cited by 150
The Genomic Landscape of Male Breast Cancers
Piscuoglio, S., Ng, C. K. Y., Murray, M. P., Guerini‐Rocco, E., Martelotto, L. G., Geyer, F. C., Bidard, F., Berman, S., Fusco, N., Sakr, R. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2840 · Cited by 152
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer
Singhal, H., Greene, M. E., Tarulli, G. A., Zarnke, A. L., Bourgo, R. J., Lainé, M., Chang, Y.-F., Ma, S., Dembo, A. G., Raj, G. V., et al. (2016) · Science Advances · doi:10.1126/sciadv.1501924 · Cited by 150
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Park, J. H., Ahn, J. H., & Kim, S. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000357 · Cited by 158
Molecular subtyping of cancer: current status and moving toward clinical applications
Zhao, L., Lee, V. H.-F., Ng, M. K., Yan, H., & Bijlsma, M. F. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby026 · Cited by 156
Molecular stratification within triple-negative breast cancer subtypes
Wang, D., Jiang, Z., Ben‐David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-55710-w · Cited by 159
A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells
Truong, D. D., Kratz, A., Park, J. G., Barrientos, E. S., Saini, H., Nguyen, T., Pockaj, B., Mouneimne, G., LaBaer, J., & Nikkhah, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2293 · Cited by 149

Authors: METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Børresen-Dale, A.-L., Brenton, J. D., Tavaré, S., Caldas, C., & Aparicio, S.
Affiliations: University of Cambridge (GB)
University of British Columbia (CA)
Oslo University Hospital (NO)
University of Nottingham (GB)
Cambridge University Hospitals NHS Foundation Trust (GB)
King's College London (GB)
University of Southern California (US)
Corresponding author: Caldas, Carlos
Aparicio, Samuel
ORCID: Curtis, Christina
Shah, Sohrab P.
Chin, Suet-Feung
Turashvili, Gulisa
Rueda, Oscar M.
Dunning, Mark J.
Speed, Doug
Lynch, Andy G.
Samarajiwa, Shamith
Yuan, Yinyin
Gräf, Stefan
Ha, Gavin
Haffari, Gholamreza
Bashashati, Ali
Green, Andrew
Provenzano, Elena
Wishart, Gordon
Pinder, Sarah
Watson, Peter
Markowetz, Florian
Murphy, Leigh
Ellis, Ian
Purushotham, Arnie
Brenton, James D.
Tavaré, Simon
Caldas, Carlos
Aparicio, Samuel
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-04-18
Volume: 486
Issue: 7403
Pages: 346-352
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10983
PMC: PMC3440846
OpenAlex: W2005895632
Cited by: 6,097
References: 32
Citations by year: 2026: 341 · 2025: 411 · 2024: 458 · 2023: 497 · 2022: 496 · 2021: 615 · 2020: 533 · 2019: 449 · 2018: 426 · 2017: 361 · 2016: 373 · 2015: 378 · 2014: 339 · 2013: 291 · 2012: 119
FWCI: 119.67
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Apollo (University of Cambridge) (submittedVersion)
Apollo
Funders: University of Southern California
Michael Smith Health Research BC
Cancer Research UK (A7199, 15601, 19556)
National Institute for Health and Care Research (ACF-2012-14-006, NF-SI-0611-10154)
University of Cambridge
King's College London
National Institutes of Health
BC Cancer Agency
NIHR Cambridge Biomedical Research Centre
National Human Genome Research Institute (P50-HG02790, P50HG002790)
Division of Mathematical Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords: breast cancer, copy number alterations, somatic copy number alterations, gene expression, single nucleotide polymorphisms, PPP2R2A, MTAP, MAP2K4, estrogen receptor-positive breast cancer, adaptive immune response, basal-like breast cancer, chromosome 5 deletion, molecular stratification, prognosis
MeSH terms: Breast Neoplasms, Female, Humans, Prognosis, Genome, Human, Gene Expression Regulation, Neoplastic, Treatment Outcome, Polymorphism, Single Nucleotide, Gene Expression Profiling, Genomics, MAP Kinase Kinase 4, Genes, Neoplasm, Kaplan-Meier Estimate, Gene Regulatory Networks, Protein Phosphatase 2, DNA Copy Number Variations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks